- Home
- CRMD vs PAXS Comparison
CRMD vs PAXS Comparison
Compare CRMD & PAXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRMD
- PAXS
- Stock Information
- Founded
- CRMD 2006
- PAXS 2021
- Country
- CRMD United States
- PAXS United States
- Employees
- CRMD N/A
- PAXS N/A
- Industry
- CRMD Biotechnology: Pharmaceutical Preparations
- PAXS Investment Managers
- Sector
- CRMD Health Care
- PAXS Finance
- Exchange
- CRMD Nasdaq
- PAXS Nasdaq
- Market Cap
- CRMD 645.0M
- PAXS 717.7M
- IPO Year
- CRMD 2010
- PAXS N/A
- Fundamental
- Price
- CRMD $6.07
- PAXS $16.07
- Analyst Decision
- CRMD Strong Buy
- PAXS
- Analyst Count
- CRMD 7
- PAXS 0
- Target Price
- CRMD $15.14
- PAXS N/A
- AVG Volume (30 Days)
- CRMD 2.1M
- PAXS 195.0K
- Earning Date
- CRMD 03-25-2025
- PAXS 01-01-0001
- Dividend Yield
- CRMD N/A
- PAXS 11.72%
- EPS Growth
- CRMD N/A
- PAXS N/A
- EPS
- CRMD N/A
- PAXS N/A
- Revenue
- CRMD $43,472,170.00
- PAXS N/A
- Revenue This Year
- CRMD $204.98
- PAXS N/A
- Revenue Next Year
- CRMD $22.54
- PAXS N/A
- P/E Ratio
- CRMD N/A
- PAXS N/A
- Revenue Growth
- CRMD N/A
- PAXS N/A
- 52 Week Low
- CRMD $3.61
- PAXS $12.57
- 52 Week High
- CRMD $13.85
- PAXS $15.93
- Technical
- Relative Strength Index (RSI)
- CRMD 22.64
- PAXS 51.65
- Support Level
- CRMD $6.92
- PAXS $15.80
- Resistance Level
- CRMD $11.32
- PAXS $16.20
- Average True Range (ATR)
- CRMD 0.65
- PAXS 0.15
- MACD
- CRMD -0.49
- PAXS 0.01
- Stochastic Oscillator
- CRMD 2.42
- PAXS 75.89
About CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets.
About PAXS PIMCO Access Income Fund of Beneficial Interest
PIMCO Access Income Fund is a non-diversified, limited-term, closed-end management investment company. The fund seeks current income as an objective and capital appreciation as a secondary objective. It achieves the investment objectives by utilizing a dynamic asset allocation among multiple sectors in the public and private credit markets, including corporate debt.